GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Provention Bio Inc (NAS:PRVB) » Definitions » Net Cash per Share

Provention Bio (Provention Bio) Net Cash per Share : $0.57 (As of Dec. 2022)


View and export this data going back to 2018. Start your Free Trial

What is Provention Bio Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Provention Bio's Net Cash per Share for the quarter that ended in Dec. 2022 was $0.57.

The historical rank and industry rank for Provention Bio's Net Cash per Share or its related term are showing as below:

PRVB' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.16   Med: 8.71   Max: 43.82
Current: 43.82

During the past 7 years, the highest Price-to-Net-Cash Ratio of Provention Bio was 43.82. The lowest was 1.16. And the median was 8.71.

PRVB's Price-to-Net-Cash is not ranked
in the Biotechnology industry.
Industry Median: 4.175 vs PRVB: 43.82

Provention Bio Net Cash per Share Historical Data

The historical data trend for Provention Bio's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provention Bio Net Cash per Share Chart

Provention Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Cash per Share
Get a 7-Day Free Trial 1.52 1.71 1.85 1.11 0.57

Provention Bio Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.11 0.89 0.89 1.57 0.57

Competitive Comparison of Provention Bio's Net Cash per Share

For the Biotechnology subindustry, Provention Bio's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Provention Bio's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provention Bio's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Provention Bio's Price-to-Net-Cash falls into.



Provention Bio Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Provention Bio's Net Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as

Net Cash per Share (A: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(165.003-115.007-0)/87.6677
=0.57

Provention Bio's Net Cash per Share for the quarter that ended in Dec. 2022 is calculated as

Net Cash per Share (Q: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(165.003-115.007-0)/87.6677
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Provention Bio  (NAS:PRVB) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Provention Bio Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Provention Bio's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Provention Bio (Provention Bio) Business Description

Traded in Other Exchanges
N/A
Address
55 Broad Street, 2nd Floor, Red Bank, NJ, USA, 07701
Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases. The company's product candidates include PRV-031, for the interception, delay, or prevention of type 1 diabetes; PRV-3279, for the potential treatment of systemic lupus erythematosus; and PRV-101.
Executives
Sessa Capital (master), L.p. 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Ashleigh Palmer director, 10 percent owner, officer: President and CEO PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833
Francisco Leon director, 10 percent owner, officer: Chief Scientific Officer C/O PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833
Jason Hoitt officer: Chief Commercial Officer C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Justin Vogel officer: Chief Accounting Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701
Rita Jain director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Sarah O'brien officer: Chief People Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701
Sessa Capital Im, L.p. 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
John Petry 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Gp, Llc 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Im Gp, Llc 10 percent owner 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Miyoko Christina Yi officer: Chief Operations Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701
Benedict Osorio officer: Chief Quality Officer ONE WORLD TRADE CENTER, 47TH FLOOR, SUITE J, NEW YORK NY 10007
Eleanor Ramos officer: Chief Medical Officer & COO ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE E, SEATTLE WA 98102
Thierry Chauche officer: Chief Financial Officer C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701